

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-37. (canceled)

38. (previously presented) The composition of claim 61 wherein the antisense oligonucleotide and the sense oligonucleotide each consist of 12 to 30 nucleosides.

39. (canceled)

40. (previously presented) The composition of claim 61 wherein the antisense oligonucleotide and the sense oligonucleotide each consist of 19 to 23 nucleosides.

41-60. (canceled)

61. (currently amended) A composition comprising a duplex consisting of an antisense oligonucleotide and a sense oligonucleotide, ~~wherein the antisense and the sense oligonucleotides~~ that are complementary to each other, ~~and~~ wherein:

the antisense oligonucleotide is complementary to a target nucleic acid;
each nucleoside of the antisense oligonucleotide comprises a 2'-fluoro modification; ~~and~~
each guanine of the natural sequence of the sense oligonucleotide is substituted with an inosine, and the sense oligonucleotide comprises at least one inosine; and
the duplex reduces the level of target nucleic acid present in a cell by at least 63 %.